Ticker brief

NBIX NEUROCRINE BIOSCIENCES INC

Consumer, Non-cyclical · Pharmaceuticals

last close
$142.70
1 day
-0.4%
14 days
+0.2%
mkt cap
$17.5B
signals 14d
7
authors 14d
5
crowd 14d
-0.03
Options inteloptions-surface reads · latest available day per source
metricreadingcontext
IV — ATM 30d43% mid · 74 pctile own 1yIV/HV 1.58× (as of 2026-10-22)
Skew — 25Δ RR 30d+0.000 70 pctile own 1ybalanced vs own range
Net dealer OI (NDOI)+0.36 elevated5-session Δ -0.08 (as of 2026-07-16)
OI alarmquietlast alarm 2025-10-30 (z=2.3)
Sentiment — last 14 days
daily mean sentiment, 2026-10-05 → 2026-10-16 · now +0.00 (−1 bearish … +1 bullish)
Who spoke5
authorgradetrader scoresignalsmean sent
@OptionsFlowBossC·2+0.00
@adamfeuersteinA-1.032-0.25
@_TP888C+0.931+0.50
@TheNewMoney_appC·1+0.20
@BiopharmIQB·1+0.00
Recent signals7of 7 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-10-16@BiopharmIQ+0.00The post summarizes opening biotech moves and their company-specific catalysts.+5.2%
2026-10-14@TheNewMoney_app+0.20Reports a large NBIX call purchase with strike, premium and expiry.+5.0%
2026-10-13@adamfeuerstein-0.65FOIA case reports link Vykat to seven deaths and 100 hospitalizations, with experts urging withdrawal.+5.6%
2026-10-13@adamfeuerstein+0.15Reports Neurocrine's defense of Vykat's benefit-risk profile amid safety concerns.+5.6%
2026-10-06@OptionsFlowBoss+0.00Reports open-interest changes, with details contained in linked media.-1.9%
2026-10-05@_TP888+0.50Reports $134K of near-term NBIX call buying at the 150 strike for October 16.-1.0%
2026-10-05@OptionsFlowBoss+0.00Requests later open-interest confirmation without stating direction.-1.0%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.